Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-191161) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan |
(2) | Registration Statement (Form S-8 No. 333-194228) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan |
(3) | Registration Statement (Form S-8 No. 333-204210) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan |
(4) | Registration Statement (Form S-8 No. 333-210694) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan |
(5) | Registration Statement (Form S-8 No. 333-215575) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan |
(6) | Registration Statement (Form S-8 No. 333-222400) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan |
(7) | Registration Statement (Form S-8 No. 333-226199) pertaining to the Onconova Therapeutics, Inc. 2018 Omnibus Incentive Compensation Plan |
(8) | Registration Statement (Form S-8 No. 333-233410) pertaining to the Onconova Therapeutics, Inc. 2018 Omnibus Incentive Compensation Plan |
(9) | Registration Statement (Form S-8 No. 333-258336) pertaining to the Onconova Therapeutics, Inc. 2021 Omnibus Incentive Compensation Plan |
(10) | Registration Statement (Form S-3 No. 333-237844) of Onconova Therapeutics, Inc. |
(11) | Registration Statement (Form S-3 No. 333-230744) of Onconova Therapeutics, Inc. |
(12) | Registration Statement (Form S-1 No. 333-211769) of Onconova Therapeutics, Inc. |
(13) | Registration Statement (Form S-1 No. 333-222374) of Onconova Therapeutics, Inc. |
(14) | Registration Statement (Form S-1 No. 333-224315) of Onconova Therapeutics, Inc. |
(15) | Registration Statement (Form S-1 No. 333-234360) of Onconova Therapeutics, Inc. |
of our report dated March 21, 2022, with respect to the consolidated financial statements of Onconova Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2021.
| /s/ Ernst & Young LLP |
Philadelphia, Pennsylvania
March 21, 2022